Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORDynamIC: 12 vs 24 Weeks Peginterferon Alfa-2a + Ribavirin in HCV Genotype 2/3
NCT00143000Phase 4Completed
- Sponsor
- NORDynamIC Study Group
- Start
- Apr 2004
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by NORDynamIC Study Group. Primary endpoint: Sustained Viral Response. Started Apr 2004; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00143000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143000.